Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Accounts Payables (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Accounts Payables for 3 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 49.32% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 49.32% increase, with the full-year FY2025 number at $9.5 million, up 49.32% from a year prior.
  • Accounts Payables was $9.5 million for Q4 2025 at Nuvation Bio, down from $15.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $22.4 million in Q2 2025 to a low of $2.2 million in Q4 2023.
  • A 3-year average of $7.9 million and a median of $5.8 million in 2024 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 421.7% in 2024; the steepest drop was 17.28% in 2024.
  • Nuvation Bio's Accounts Payables stood at $2.2 million in 2023, then surged by 187.37% to $6.3 million in 2024, then surged by 49.32% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Accounts Payables are $9.5 million (Q4 2025), $15.4 million (Q3 2025), and $22.4 million (Q2 2025).